We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DAN:NYSEDana Incorporated Analysis

Data as of 2026-03-28 - not real-time

$32.55

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Dana Incorporated trades around $32.55, comfortably above its 20‑day SMA of $32.73 and 50‑day SMA of $32.09, indicating a short‑term bullish bias. However, the MACD histogram is negative (-0.054) and the signal line is bearish, while the RSI sits near the midpoint at 50.2, suggesting limited upside momentum. Volatility is elevated at 34.6% 30‑day and beta exceeds 1.5, reflecting a stock that moves sharply with the market. The current price also sits about $11 above the DCF‑derived fair value of $21.53, implying an overvalued market stance despite a modest upside/downside estimate of +17.6%.
Fundamentally, Dana posted 5.2% revenue growth YoY but margins remain thin (gross 8%, operating 4.2%) and ROE is negative. The balance sheet carries a high debt load (debt‑to‑equity > 390) and a payout ratio near 91%, raising concerns about dividend sustainability. The recent appointment of Byron Foster as CEO and the “Dana 2030” strategic plan targeting $10 B revenue, 15% EBITDA and a $2 B buyback signal a clear push toward growth and shareholder returns, but execution risk remains high.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above short‑term moving averages but MACD bearish
  • Support level at $30.59 holding firm
  • Increasing volume indicating active trading

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • New CEO and Dana 2030 plan targeting higher EBITDA and buybacks
  • Revenue growth of 5.2% and forward EPS upside
  • Attractive dividend yield of 1.47% despite sustainability concerns

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Current price well above DCF fair value, suggesting valuation pressure
  • High leverage and negative ROE increase structural risk
  • Long‑term EV and electrification exposure could improve margins if executed

Key Metrics & Analysis

Financial Health

Revenue Growth5.20%
Profit Margin1.13%
P/E Ratio9.0
ROE-4.27%
ROA1.61%
Debt/Equity394.22
P/B Ratio4.4
Op. Cash Flow$512.0M
Free Cash Flow$327.0M

Technical Analysis

TrendBullish
RSI50.2
Support$30.59
Resistance$34.86
MA 20$32.73
MA 50$32.09
MA 200$23.03
MACDBearish
VolumeIncreasing
Fear & Greed Index65.98

Valuation

Fair Value$21.53
Target Price$38.29
Upside/Downside17.62%
GradeOvervalued
TypeBlend
Dividend Yield1.47%

Risk Assessment

Beta1.53
Volatility34.60%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.